These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Treatment of macroprolactinomas with quinagolide (Norprolac)]. Tabarin A; Catargi B Ann Endocrinol (Paris); 1997; 58(2):87-94. PubMed ID: 9239226 [TBL] [Abstract][Full Text] [Related]
4. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse. Rohmer V; Freneau E; Morange I; Simonetta C Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391 [TBL] [Abstract][Full Text] [Related]
7. Prolactinoma and pregnancy. Randeva HS; Davis M; Prelevic GM BJOG; 2000 Sep; 107(9):1064-8. PubMed ID: 11002946 [No Abstract] [Full Text] [Related]
8. Cabergoline treatment of pregnant women with macroprolactinomas. Laloi-Michelin M; Ciraru-Vigneron N; Meas T Int J Gynaecol Obstet; 2007 Oct; 99(1):61-2. PubMed ID: 17602689 [No Abstract] [Full Text] [Related]
9. Prolactinomas and pregnancy. Molitch ME Clin Endocrinol (Oxf); 2010 Aug; 73(2):147-8. PubMed ID: 20550542 [No Abstract] [Full Text] [Related]
10. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy. Colao A; Lombardi G J Clin Endocrinol Metab; 1997 Aug; 82(8):2756. PubMed ID: 9253368 [No Abstract] [Full Text] [Related]
12. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Delgrange E; Crabbé J; Donckier J Horm Res; 1998; 49(5):250-3. PubMed ID: 9568811 [TBL] [Abstract][Full Text] [Related]
13. [Update on endocrinology: management of prolactinomas during pregnancy]. Cecenarro LA; Estario P; Estario ME; Fux-Otta C Rev Fac Cien Med Univ Nac Cordoba; 2015; 72(3):170-4. PubMed ID: 26913801 [TBL] [Abstract][Full Text] [Related]
14. Quinagolide in the management of prolactinoma. Schultz PN; Ginsberg L; McCutcheon IE; Samaan N; Leavens M; Gagel RF Pituitary; 2000 Dec; 3(4):239-49. PubMed ID: 11788012 [TBL] [Abstract][Full Text] [Related]
16. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715 [TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502. Glaser B; Nesher Y; Barziliai S J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398 [TBL] [Abstract][Full Text] [Related]
18. [Pituitary apoplexy in a pregnant woman with cystic microprolactinoma]. Querol Ripoll R; Cámara Gómez R; Del Olmo García M; Simal Julián JA; Merino Torres JF Endocrinol Nutr; 2015 Apr; 62(4):200-2. PubMed ID: 25732323 [No Abstract] [Full Text] [Related]
20. [Use of bromocriptine during pregnancy and appearance of partial empty sella turcica in women with prolactinoma]. López de la Torre Casares M; Rodríguez Poyo-Guerrero P; Garrido Pérez M; Moreno Esteban B Rev Clin Esp; 1991 Nov; 189(7):343-4. PubMed ID: 1767093 [No Abstract] [Full Text] [Related] [Next] [New Search]